Bristol-Myers Squibb Co. (BMS) made clear in its conference call on consensus-beating fourth quarter earnings that the firm will continue efforts to make its immuno-oncology presence "strong, deep and wide," but officials also made note of the newer push in antifibrotics via the whopper deal in November with Galecto Biotech AB and another earlier this month with the California Institute for Biomedical Research.